Phaseline

Companies › Woolsey Pharmaceuticals

Woolsey Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 5 Phase 2; Neurology, Genitourinary, Oncology; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Fasudil (WP-0512)
Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 2Amyotrophic Lateral Sclerosis; Prostate Cancer; Prostate CA; Cognitive Decline, Mild …Jan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07250542Fasudil (WP-0512)Phase 2Prostate CancerOncologyDec 2026
NCT06861192Fasudil (WP-0512)Phase 2Prostate CAGenitourinaryMar 2027
NCT06362707Fasudil (WP-0512)Phase 2Cognitive Decline, MildOncologyJan 2028
NCT06890858Fasudil (WP-0512)Phase 2Ovarian CancerOncologyJan 2028
NCT05218668Fasudil (WP-0512)Phase 2Amyotrophic Lateral SclerosisNeurologyJan 2029

Targets

ROCK2 (1) ROCK1 (1)

Companies with the same targets

Sanofi Aurion Biotech Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Leadiant Biosciences Kissei Pharmaceutical Shanghai Jiaolian Drug Research and Development Exciva Guangzhou Novaken Pharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.